Background: Clear cell carcinoma of the endometrium (CCE) is a rare subtype of endometrial cancer (EC) associated with worse prognosis when compared to other high grade EC subtypes. We aim to evaluate molecular, genomic and protein expression patterns in a large cohort of CCEs in order to direct patients to rational therapeutic strategies and clinical trials.

Methods: Out of 3133 EC submitted to Caris Life Sciences from March 2011 to July 2014, 136 CCEs were identified based on reported pathology. Testing was ordered per physician request and included a combination of sequencing (Sanger or next generation sequencing), protein expression (immunohistochemistry), and /or gene amplification (FISH/CISH).